Sequoia Financial Advisors LLC Grows Stock Position in Eli Lilly and Company $LLY

Sequoia Financial Advisors LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 19.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 140,201 shares of the company’s stock after purchasing an additional 22,410 shares during the quarter. Eli Lilly and Company accounts for approximately 0.3% of Sequoia Financial Advisors LLC’s holdings, making the stock its 28th biggest position. Sequoia Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $109,291,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Nuveen LLC purchased a new position in Eli Lilly and Company during the first quarter worth about $4,613,912,000. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,024.67 on Friday. The stock has a fifty day moving average price of $826.89 and a 200 day moving average price of $780.14. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $968.70 billion, a PE ratio of 66.97, a P/E/G ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Berenberg Bank restated a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft cut their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Finally, Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a research report on Monday, November 10th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,015.11.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.